Tofawin 5

Usage of Tofawin 5 Tofawin 5 is indicated for: Rheumatoid Arthritis (RA) – moderate to severe, as monotherapy or in combination with methotrexate or other DMARDs Psoriatic Arthritis (PsA) – in patients with inadequate response to NSAIDs or DMARDs Ulcerative Colitis (UC) – moderate to severe cases not responding to standard therapies Off-label: Ankylosing spondylitis, alopecia areata (emerging use), and COVID-19-related hyperinflammation (under clinical study) Mechanism of Action Tofacitinib inhibits Janus kinase (JAK) enzymes , primarily JAK1 and JAK3 , interfering with the JAK-STAT signaling pathway , which transmits signals from cytokine receptors to the cell nucleus. This leads to: Suppression of pro-inflammatory cytokines (IL-6, IFN-γ, IL-2, etc.) Reduction in immune cell activation Modulation of autoimmune and inflammatory responses Key Benefits ✅ Rapid onset of action in reducing joint pain and swelling (RA & PsA) ✅ Oral administration – non-injectable alternative to biologics ✅ Effective in patients unresponsive to methotrexate or TNF inhibitors ✅ Steroid-sparing in ulcerative colitis ✅ Improves quality of life and physical functioning Common Side Effects Upper respiratory tract infections Headache Diarrhea or GI upset Hypertension Increased liver enzymes Serious risks include infections , herpes zoster , thromboembolism , and malignancy in long-term use. Careful monitoring is essential. Precautions Screen for tuberculosis , hepatitis B/C , and latent infections

No questions yet. Ask the first one: the supplier is notified and the answer is posted here for every buyer.